To evaluate the efficacy of a single dose of 150 x 106 AMDC-USR in the reduction of stress incontinence episode frequency (IEF) in adult female subjects at 12 months post-treatment.

The purpose of this study is to see if establishing a reproductive health program will help to address the reproductive needs of women in the 15-55 age group who are diagnosed with cancer. This will be done through an intervention.

The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body’s immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help prevent your cancer from returning, but it could also cause side effects. This research study will allow researchers to find out whether this different treatment is better, the same, or worse than the usual treatment for lung cancer.

this trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you.

The purpose of this study is to see if adding either prochlorperazine or olanzapine to the standard antiemetic regimen of Akynzeo and dexamethasone at chemotherapy cycle 2 can improve chemotherapy-related nausea and vomiting in people who experienced it at chemotherapy cycle 1.  We also want to find out if either of these drugs is more effective than the other in controlling chemotherapy-related nausea and vomiting.

The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer. Some studies have suggested that aspirin may lower the risk of breast cancer coming back, but others have not, so we do not know if aspirin will help decrease breast cancer recurrence. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo. A placebo is a tablet that looks like the study drug (aspirin), but contains no medication.

This study is for people with superficial bladder cancer that has not invaded into the bladder muscle wall and that did not respond to Bacillus Calmette-Guerin (BCG). Unless the person is in a study, when people do not respond to BCG, or the FDA approved drug Valrubicin, or other treatments individualized to a person’s clinical situation, treatment usually involves removal of the bladder (cystectomy).   This study will test how effective the investigational drug atezolizumab is at keeping non-muscle invasive bladder cancer from coming back or getting worse. The study drug, atezolizumab, although approved by the FDA to treat other stages of bladder and lung cancers, is not approved by the FDA for treatment of bladder cancer at this early stage.

This study is for people who have high grade bladder cancer that has not entered the muscle.  In the U.S., people who are not in a study are usually treated with BCG LIVE (TICE® BCG) (an abbreviation for Bacillus Calmette–Guérin), which is a bacteriu.  It is given directly into the bladder and infects the bladder, BCG stimulates the immune system to fight the bladder cancer. BCG is usually tolerated well by patients with normal immune system function.

For patients who receive the usual approach for bladder cancer, about 40 out of 100 are free of cancer at five years.

This study is being done to answer the following question:

Can we lower the chance of getting painful mouth sores by treating you with a dexamethasone mouthwash at the start of your cancer treatment?

We are doing this study to find out if this approach is better or worse than the usual approach for preventing painful mouth sores.  The usual approach is defined as care most people get for painful mouth sores.

The purpose of this study is to learn if the HBV medicine called tenofovir alafenamide (TAF) can help reduce the chance that HBV gets worse or comes back during cancer treatment. It is not known if starting TAF  with chemotherapy is better than waiting until HBV returns or becomes more active. 

Current guidelines say that doctors should give Colony-stimulating factors (CSFs) during cancer treatment based on how likely it is that the drugs will raise the risk of febrile neutropenia. Research shows that many doctors do not follow these guidelines. This may be harming patients.

The main purpose is to determine whether screening for breast cancer with tomosynthesis mammography is superior to digital mammography. This study will also compare whether there is a difference in the number of additional tests recommended after tomosynthesis mammography and digital mammography.

The purpose of this study is to look at the effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.  The addition to the usual chemotherapy could prevent your cancer from returning, but it could also cause side effects.  This study will allow the researchers to know whether giving carboplatin with the usual chemotherapy is better, the same, or worse than giving the usual chemotherapy. 

The primary objective is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo

Researchers at LSU Health Shreveport are looking for volunteers to participate in a study to better understand Brain and Heart health, including Alzheimer's Research.

This is a Phase 2, multicenter, randomized, active-controlled, open-label study with a 3-arm parallel design. It is planned to be conducted at investigator sites in the United States, with other countries to be considered. Approximately 690 infants aged ³42 to £98 days will be randomized (1:1:1) to receive a vaccine series with:

· c7vPnC coadministered with Prevnar 13 (Group 1 - coadministration);

· c7vPnC given 1 month after Prevnar 13 (Group 2 - staggered administration); or

· Prevnar 13 alone as the active control group (Group 3 - control with Supplemental Dose). A single dose of c7vPnC will be administered after the Prevnar 13 series is completed in this group.

This is a phase 1, open-label, single-dose, multicenter study to determine the PK, safety, and tolerability of IV eravacycline in children 8 to <18 years of age with suspected or confirmed bacterial infection who are receiving systemic antibiotic therapy, other than eravacycline. Eravacycline will be administered as a single IV dose using the optimum dosage determined from PK/pharmacodynamic (PD) modeling and -model-based simulations of phase 1, 2, and 3 adult data. Blood samples will be collected for PK analysis at predetermined timepoints (see PK Assessments).

Comparing open surgical bypass to endovascular therapy in CLI patients with a composite clinical endpoint denoted as Major Adverse Limb Event free survival (MALE-free survival). MALE-free survival captures major clinical limb-events (above ankle amputation, need for repeat bypass, interposition graft, thrombectomy, thrombolysis), and death. However the BEST CLI trial does not capture bypass or stent failure as it does not mandate surveillance duplex ultrasonography.

For the treatment of new onset respiratory tract Pseudomonas aeruginosa infection/colonization

To understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for ICD therapy. The incidence of all-cause shocks in subjects programmed with shocks only will be compared with subjects programmed to standard therapy (ATP and shock) to assess equivalency.

Multivariate analyses will also be performed to determine which baseline clinical factors are associated with the use of ATP, bradycardia pacing, and the need for CRT-D pacing therapy.

A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support

To assess the effect of a customized, multifaceted, health system-level QI program compared with usual care on HF outcomes (i.e., composite of HF readmissions or all-cause mortality) and HF quality metrics (i.e., as assessed by an opportunity-based composite score) in the year following discharge for participants with acute HF and reduced left ventricular ejection fraction(LVEF)

The primary objective is to determine the inter-rater reliability between multiple health care professional (HCP) ratings of RSV severity in neonates, infants, and children hospitalized with RSV infection using the PRESORS.

To describe the population pharmacokinetics of high-dose parenteral acyclovir (60 mg/kg/day) in neonates with virologically confirmed neonatal HSV disease and who are receiving acyclovir as standard of care.

To determine the efficacy of AMAG-423 for the prevention of intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), or death in the offspring of women with severe preeclampsia

To prospectively evaluate the impact of one versus two courses of antenatal steroids on the incidence of major neonatal morbidity including respiratory distress syndrome in pregnant women with a singleton gestation between 24w0d to 32w6d gestation who have documented premature rupture of the membranes.

The study objective is to demonstrate that the 6-month cumulative patency of grafts connected with the InterGraft™ VIG connectors is similar to that of grafts connected using standard sutured anastomoses.

Pediatric treatment for the flu

To evaluate the effectiveness of best endovascular (EVT) compared to best surgical (OPEN) revascularization in patients with CLI

This is an open-label, multi-center, clinical sampling study to assess ganciclovir pharmacokinetics and pharmacodynamics in premature infants undergoing antiviral therapy for CMV.